Drug updated on 12/11/2024
| Dosage Form | Tablet (oral; 185 mg) |
| Drug Class | Penicillin class antibacterials |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.
Latest News
Summary
- This summary is based on the review of one randomized controlled trial. [1]
- Of the 143 non-pregnant women aged 18-60 included in the final analysis, 53.8% (77 women) recovered without antibiotics, while 46.2% (66 women) were prescribed antibiotics following initial ibuprofen treatment for uncomplicated UTIs. No significant baseline predictors were identified for the need for antibiotic treatment in the adjusted model. The area under the curve (AUC) for the model was 0.66 (95% confidence interval (CI): 0.57 to 0.74), indicating moderate predictive accuracy for antibiotic use.
- There is no safety information available in the reviewed studies.
- There is no population type or subgroup information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Pivya (pivmecillinam) Prescribing Information. | 2024 | Utility therapeutics Ltd., UK |
Randomized Controlled Trials
| Document Title | Sex Distribution | Year | Source |
|---|---|---|---|
| Predicting the use of antibiotics after initial symptomatic treatment of an uncomplicated urinary tract infection: analyses performed after a randomised controlled trial | 143Subjects F: 100% M: null% | 2020 | BMJ Open |
Sex Distribution:
F:100%
M:%
143Subjects
Year:
2020
Source:BMJ Open